Drug offers hope in treating ocular melanoma

Video

Richard Carvajal, MD, associate professor at Columbia University Medical Center, discusses one drug potential to treat ocular melanoma at ARVO 2018 in Honolulu.

The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or UBM Medica.

Richard Carvajal, MD, associate professor at Columbia University Medical Center, discusses one drug potential to treat ocular melanoma at ARVO 2018 in Honolulu.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Dr. Julie Rodman previews her SECO presentations
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Dr Carolyn Majcher chats about GA and posterior uveitis at AAOpt 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Related Content
Early detection and management of AMD are crucial to preserving visual function, says Michael Cymbor, OD, FAAO. Image credit: ©Graphicroyalty - stock.adobe.com

The optometrist’s role in managing age-related macular degeneration with OCT-A

Michael Cymbor, OD, FAAO
April 24th 2025
Article
Optometry Times You and Eye

You and Eye: What optometrists need to know about low vision

Miriam Korik, OD;Emily Kaiser Maharjan, Assistant Managing Editor
March 13th 2024
Podcast
FDA issues CRL for extended dosing regiment for Eylea HD for wet AMD, DME, and DR - Image credit: Adobe Stock / ©Michele Ursi

Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA

Martin David Harp, Editor, Ophthalmology Times;Hattie Hayes;Kassi Filkins, Editor
April 21st 2025
Article
Advances in treatment for geographic atrophy

Advances in treatment for geographic atrophy

David S. Boyer, MD;Tina Mac Donald, OD, CDCES, FAAO;Leo P. Semes, OD, FAAO
October 11th 2023
Podcast
Opus Genetics issues 1-month pediatric gene therapy results - Image credit: Adobe Stock / ©Andrii Yalanskyi

Opus Genetics issues 1-month pediatric gene therapy results

Lynda Charters
April 9th 2025
Article
FDA accepts updated BLA from Outlook Therapeutics for ONS-5019 for wet AMD - Image credit: Adobe Stock / ©Have a nice day

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD

Martin David Harp, Editor, Ophthalmology Times
April 9th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.